Although ARID1A alterations are most prominently described in ovarian and endometrial cancers, their identification in this skull-based lesion aligns with increasing evidence that epigenetic dysregulation may be a crucial driver of neoplastic transformation in plasmacytomas (1, 34, 35). This evidence concerns the gene ARID1A and plasmacytoma.